The HNF4A Knockout HeLa Polyclonal Cells product comprises a heterogeneous population of HeLa cells that have undergone CRISPR/Cas9-mediated gene disruption targeting the HNF4A locus. This polyclonal knockout pool is designed to provide a loss-of-function model for studying HNF4A-dependent transcriptional programs. The cells are delivered as a ready-to-use polyclonal population, enabling the analysis of gene disruption effects without the need for single-cell cloning or isolation. This format is well-suited for experiments where a representative knockout population recapitulates the biological consequences of target-gene ablation across diverse genetic backgrounds within the batch.
HeLa cells serve as the host background, originally derived from a human cervical adenocarcinoma. This immortalized epithelial cell line is positive for human papillomavirus type 18 (HPV-18), leading to the expression of E6 and E7 oncoproteins that degrade p53 and inactivate Rb, respectively. Consequently, HeLa cells exhibit rapid, adherent proliferation and loss of normal cell cycle control. Their extensive characterization and ease of culture have established HeLa as a versatile model system for cell biology, cancer research, and virology, making them a practical chassis for investigating gene function in an epithelial context.
HNF4A encodes a nuclear receptor transcription factor that binds DNA as a homodimer to orchestrate genes critical for hepatocyte differentiation, epithelial junction formation, and systemic metabolism. Its activity is regulated by upstream factors including HNF1A, GATA4, FOXA2, ONECUT1, and PPARGC1A, while the receptor interacts with co-regulators such as NCOR1 and NCOA2. Downstream, HNF4A directly promotes the expression of targets like GLUT2, PEPCK, G6PC, CYP7A1, APOB, and APOA1. Mechanistically, HNF4A functions as a master regulator by integrating signals from glucagon, insulin, and glucocorticoids, and it participates in feed-forward loops with HNF1A and SHP to control glucose uptake, gluconeogenesis, bile acid synthesis, and lipid transport.
Disruption of HNF4A in HeLa cells compromises the transcriptional regulation of metabolic and epithelial polarity genes, producing a model that recapitulates key aspects of metabolic dysregulation and loss of cell junction integrity. Although HeLa cells do not possess a full hepatic phenotype, HNF4A knockout in this background impairs the expression of epithelial junction components downstream of HNF4A, such as those involved in tight junction assembly seen in hepatocytes. This perturbation makes the model useful for exploring how HNF4A loss contributes to diseases like maturity-onset diabetes of the young type 1 (MODY1), hyperinsulinemic hypoglycemia, hepatocellular carcinoma, and inflammatory bowel disease within a well-characterized, proliferative epithelial framework.
This knockout cell product enables a wide array of experimental applications. Researchers can employ RT-qPCR and western blotting to quantify changes in HNF4A target genes (e.g., GLUT2, CYP7A1) and protein levels, complemented by immunofluorescence staining for tight junction markers such as ZO-1. Functional assays measuring glucose uptake and production, lipid accumulation, and bile acid synthesis allow dissection of metabolic reprogramming. Transcriptomic profiling via RNA-seq and chromatin immunoprecipitation?CqPCR for HNF4A binding sites provide genome-wide insights. Additionally, migration and invasion assays, combined with drug sensitivity studies, facilitate investigations into cancer progression and therapeutic responses. For further details, please contact Ascent Research.
